Galenica submits US NDA for chewable, iron-based phosphate binder
This article was originally published in Scrip
Executive Summary
Swiss drug maker Galenica submitted a new drug application (NDA) to the US FDA for PA21, a chewable, iron-based phosphate binder, as a treatment to control of hyperphosphatemia in patients with chronic kidney disease (CKD).